-
Category
Proteins & Peptides
-
Long description
Mutations in elongation of very long-chain fatty acid-4 (ELOVL4) are associated with autosomal dominant Stargardt-like macular degeneration (STGD3), with a five base-pair (5 bp) deletion mutation resulting in the loss of 51 carboxy-terminal amino acids and truncation of the protein. Elovl4 is expressed in the retina and only a limited number of mammalian other tissues, including skin, with unknown function. In a mouse model with the 5-bp deletion in the Elovl4 gene, mice in the heterozygous state (Elovl4(+/del)) demonstrate progressive photoreceptor degeneration. Homozygous mice (Elovl4(del/del)) display scaly, wrinkled skin, have severely compromised epidermal permeability barrier function, and die within a few hours after birth. Lipid analyses of epidermis from Elovl4(del/del) mice show a decrease in very long-chain fatty acids (VLFAs) in both the ceramide/glucosylceramide and the free fatty-acid fractions. ELOVL4 is required for generating VLFA critical for epidermal barrier function.
-
Antibody come from
Synthetic peptide derived from human CALHM1 protein.
-
Other description
Provided as solution in phosphate buffered saline with 0.08% sodium azide.
-
Clone
not specified
-
Antigen antibody binding interaction
ELOVL4 - Blocking Peptide
-
Antibody is raised in
Rabbit
-
Antibody s reacts with
Human
-
Antibody s reacts with these species
This antibody doesn't cross react with other species
-
Antibody s specificity
No Data Available
-
Application
Western Blot
-
Antibody s suited for
Antibody can be used for Western blotting (1-5 µg/ml). Optimal concentration should be evaluated by serial dilutions.
-
Storage
-20ºC
-
Relevant references
1. Dreses-Werringloer, U., et la. A Polymorphism in CALHM1 Influences Ca2+ Homeostasis, Ab Levels, and AlzheimerÕs Disease Risk. Cell 2008, 133, 1149-1161_x000B__x000B_2. Bertram, L., et al. 'No association between CALHM1 and AlzheimerÕs disease risk.' Cell 2008, 135(6), 993-994._x000B__x000B_3. Cui, P.J., et al. 'CALHM1 P86L polymorphism is a risk for AlzheimerÕs Disease in the Chinese population.' J. Alzheimers Dis. 2009, Epub ahead of
-
Protein number
see ncbi
-
Warnings
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. This datasheet is as accurate as reasonably achievable, but Nordic-MUbio accepts no liability for any inaccuracies or omissions in this information.
-
-
Test
You can block the antibody by the specific target amino acid sequence of peptide.
-
Properties
blocking peptide
-
Description
Peptides short amino acid chains or epitopes or blocking antagonists. The shortest peptides are dipeptides, consisting of 2 amino acids joined by a single peptide bond, followed by tripeptides, tetra peptides, ... till polypeptides that are long, continuous, and unbranched synthetic peptide chains. These biological oligomers and polymers can be Solid-phase peptide synthesis (SPPS), or in continue produced for custom peptide synthesis projects. The High-efficiency solid phase peptide synthesis (HE-SPPS) is give very low production costs.
